Retatrutide Storage and Stability Retatrutide stability follows the standard GLP-1 family profile: For practical storage protocols, see our guide on how long do peptides last at room temperature
In comparison, the STEP-1 trial reported that 2.4mg/weekly semaglutide led to side effects in 89.7% of the subjects, with the most common complaints being [17]: Nausea (44.2% of subjects) Diarrhea (31.5%) Vomiting (24.8%) Constipation (23.4%) Dyspepsia (10.3%) Abdominal pain (10% Gallbladder-related events (2.6%) The majority of gastrointestinal reactions were of mild to moderate intensity, temporary, and resolved without needing a permanent halt in treatment
An interruption of just six months before resuming treatment still reduced the cardiovascular benefit, leading to a 4% to 8% increased risk compared to continuous use
This level of traceability is a powerful tool for risk management
Learn how our telehealth programs and refill coordination work on our Get Started page
Guan R, Yang Q, Yang X, Du W, Li X, Ma G (2022) Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: a Bayesian network meta-analysis